Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | ![]() | 08 Nov 2022 |